natalia 0 0 Oncology 09/2016 Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients Precison: Lung Cancer R&D SummitRead More
natalia 0 0 Oncology 08/2016 DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics Journal of Cell SignalingRead More
Graviton 0 Oncology 06/2016 Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 ASCO Annual MeetingRead More
Graviton 0 Oncology 04/2016 FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study AACR Annual MeetingRead More
Graviton 0 Oncology 04/2016 Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640 AACR Annual MeetingRead More
Graviton 0 Oncology 03/2016 Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 International Congress on Targeted Anticancer TherapiesRead More
Graviton 0 Oncology 02/2016 Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement Keystone Symposium - New Frontiers in Understanding Tumor MetabolismRead More
Graviton 0 0 Oncology 02/2016 Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement Keystone Symposium - New Frontiers in Understanding Tumor MetabolismRead More
Graviton 0 Oncology 11/2015 A First in Human Study of the First in Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640. Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity EORTC-NCI-AACR International ConferenceRead More
Graviton 0 Oncology 11/2015 Biomarker Analyses from Dose Escalation and Expansion Phases of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients EORTC-NCI-AACR International ConferenceRead More